"The Digestive Health Center of Louisiana (DHCLA) was founded to promote and preserve the health of the Capitol Region. Completed in 2005, this state of the art building brings Gastroenterology Associates and Louisiana Endoscopy Center together under one roof, creating the most complete and comprehensive gastroenterology health center in the state. Whether you are a patient, potential patient, referring doctor, or human resources professional, we appreciate the opportunity to serve you."

During the past decade, Texas Digestive Disease Consultants conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 7 clinical trials were completed, i.e. on average, 58.3% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 7 clinical trials were completed. i.e. 87.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Texas Digestive Disease Consultants" #1 sponsor was "Arena Pharmaceuticals" with 2 trials, followed by "Eli Lilly and Company" with 2 trials sponsored, "Pfizer" with 2 trials sponsored, "Bristol-Myers Squibb" with 1 trials sponsored and "GB004, Inc." with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Texas Digestive Disease Consultants" #1 collaborator was "Arena is a wholly owned subsidiary of Pfizer" with 2 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Texas Digestive Disease Consultants" are "Ulcerative Colitis" (8 trials), "Crohn Disease" (1 trials), "Gastroesophageal Reflux Disease (GERD)" (1 trials), "NASH - Nonalcoholic Steatohepatitis" (1 trials) and "Non Alcoholic Steatohepatitis (NASH)" (1 trials). Many other conditions were trialed in "Texas Digestive Disease Consultants" in a lesser frequency.

Most popular intervention types in "Texas Digestive Disease Consultants" are "Drug" (11 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Etrasimod" (4 trials), "Adalimumab (40 mg)" (1 trials), "BMS-986165" (1 trials) and "GB004" (1 trials). Other intervention names were less common.

The vast majority of trials in "Texas Digestive Disease Consultants" are 12 trials for "All" genders.

Currently, there are NaN active trials in "Texas Digestive Disease Consultants". undefined are not yet recruiting, 4 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Texas Digestive Disease Consultants, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Texas Digestive Disease Consultants, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".